Author Archives: Marisa Wexler MS

Worse Physical Condition, Lung Function Predict Shorter Lives Without Transplant in SAPH Patients, Study Finds

People with sarcoidosis-associated pulmonary hypertension who have reduced physical fitness or worse gas exchange capacity live significantly shorter times without requiring a transplant, a new study indicates. The study, “Physiological Predictors of Survival in Patients with Sarcoidosis Associated Pulmonary Hypertension,” was published in the European Respiratory…

FDA Approves Ofev for Sarcoidosis and Other Interstitial Lung Diseases

Boehringer Ingelheim‘s Ofev (nintedanib) has been approved in the U.S. as the first treatment for chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. This approval by the United States Food and Drug Administration (FDA) includes sarcoidosis, autoimmune ILDs, unclassifiable ILDs, chronic hypersensitivity pneumonitis,…

Acthar Gel May Improve Sarcoidosis Symptoms, Real-world Study Shows

Acthar Gel (repository corticotropin injection, or RCI) can improve sarcoidosis symptoms, a real-world study shows. Titled “Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records,” the study was published in the journal Therapeutic Advances in Respiratory Disease. Acthar Gel, marketed…